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Apolipoprotein C-III as a Potential Modulator of the Association
Between HDL-Cholesterol and Incident Coronary Heart Disease
Majken K. Jensen, PhD; Eric B. Rimm, ScD; Jeremy D. Furtado, ScD; Frank M. Sacks, MD
Background—-High-density lipoproteins (HDL) are structurally and metabolically heterogeneous and subclasses with differential
effects on coronary heart disease (CHD) might exist. Apolipoprotein (apo) C-III, a small proinﬂammatory protein that resides on the
surface of lipoproteins, enhances the atherogenicity of VLDL and LDL particles, but little is known about the role apoC-III on HDL.
We investigated whether the presence or absence of apoC-III differentiates HDL into subtypes with nonprotective or protective
associations with risk of future CHD.
Methods and Results—-High-density lipoprotein cholesterol (HDL-C) levels were measured in plasma separated according to
apoC-III (by immunoafﬁnity chromatography) in two prospective case-control studies nested within the Nurses’ Health and the
Health Professionals Follow-Up Studies. Baseline was in 1990 and 1994, and 634 incident CHD cases were documented through
10 to 14 years of follow-up. The relative risk of CHD per each standard deviation of total HDL-C was 0.78 (95% conﬁdence intervals,
0.63–0.96). The HDL-C subtypes were differentially associated with risk of CHD, HDL-C without apoC-III inversely and HDL-C with
apoC-III directly (P=0.02 for a difference between the HDL types). The relative risk per standard deviation of HDL-C without apoC-III
was 0.66 (0.53 to 0.93) and 1.18 (1.03 to 1.34) for HDL-C with apoC-III. HDL-C with apoC-III comprised ∼13% of the total HDL-C.
Adjustment for triglycerides and apoB attenuated the risks; however, the two HDL-C subgroups remained differentially associated
with risk of CHD (P=0.05).
Conclusion—-Separating HDL-C according to apoC-III identiﬁed two types of HDL with opposing associations with risk of CHD. The
proatherogeniceffectsofapoC-III,asacomponentofVLDLandLDL,mayextendtoHDL.(JAmHeartAssoc.2012;1:jah3-e000232
doi: 10.1161/JAHA.111.000232.)
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P
opulationstudieshaveshownthatlow-densitylipoprotein
cholesterol (LDL-C) directly and high-density lipoprotein
cholesterol (HDL-C) inversely predict risk of coronary heart
disease (CHD).1–5 Although statins and other classes of drugs
efﬁciently reduce LDL-C and concomitantly lower the risk of
cardiovascular events,6 evidence for independent atheropro-
tective effects of raising HDL-C is inconsistent.7 The anti-
atherogenicpropertiesoftheHDLparticleincludetheabilityto
promote transport of cholesterol from peripheral tissues such
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as the artery wall to the liver, as well as anti-inﬂammatory,
anti-apoptotic, nitric oxide-promoting, prostacyclin-stabilizing,
and platelet-inhibiting functions.8 However, changes in HDL-
C among all trials using hypolipidemic drugs did not inde-
pendently predict changes in CHD;7,9 and the lack of CHD
reduction in trials of a drug that raises HDL-C by an unprece-
dented amount using a novel mechanism suggests the pos-
sibility that HDL-C may contain protective and nonprotective
components.10,11
The metabolic heterogeneity of HDL particles may under-
lie the inconsistency between epidemiological studies, consis-
tently showing independent risk prediction, and experimental
approachesinclinicaltrialsoflipidtreatments.HDLcomprises
a diverse group of lipoproteins with substantial differences
in size and density, and composition of lipids and proteins
that inﬂuence the functional properties and metabolism of
the particles. Thus, it is likely that subpopulations of HDL ex-
ist with more or less anti-atherogenic potential.12–15 Several
large-scale epidemiologic studies have investigated the risk of
CHD when HDL was separated by size. In some studies the
concentration of small size HDL, or increase in small size HDL
caused by gemﬁbrozil, is associated with lower incidence of
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Figure 1. Flowchart for the nested case-control studies.
CHD;16–18 in other studies, large size HDL had the protective
associations;19,20 and in another cohort study, very large HDL
particle size was directly associated with incidence of CAD.21
Thus, it remains inconclusive whether any of these techniques
lead to any gain in information in terms of the identiﬁcation
of HDL subclasses with variable anti-atherogenic potential.
Efforts to identify characteristics that may modulate the func-
tional properties and metabolism of the HDL particle are im-
portant to improve the understanding of the atherosclerotic
process and to prevent and treat cardiovascular diseases.
In previous work, we found that apolipoprotein (apo) C-
III, a small protein that resides on the surface of some
lipoproteins,22,23 provoked inﬂammatory and atherogenic re-
sponses in cells that are involved in atherosclerosis.24,25 The
plasma concentration of apolipoprotein C-III (apoC-III) in VLDL
and LDL, or the concentration of LDL that has apoC-III pre-
dicted risk of cardiovascular disease (CVD) or progression of
coronary atherosclerosis independently of standard lipid risk
factors.26–29 Although HDL particles exist both with and with-
out apoC-III, little is known about the role of apoC-III in re-
lation to HDL function or risk of CHD. Because apoC-III may
inhibit anti-atherogenic actions of HDL,25
we aimed to compare plasma con-
centrations of total HDL, HDL that
has apoC-III, and HDL without apoC-
III as predictors of the risk of CHD
in two prospective studies of US
women and men initially free of CHD.
Methods
Design and Population
The Nurses’ Health Study (NHS) enrolled
121 701 female nurses aged 30 to 55
years in 1976 and the Health Profes-
sionals Follow-Up Study (HPFS) enrolled
51 529 males aged 35 to 75 years in
1986. Participants of both cohorts ﬁlled
out questionnaires on lifestyle and medi-
cal history and have since been followed
with biennial questionnaires to record
newly diagnosed illnesses and to update
lifestyle information.30,31 Between 1989
and 1990, a blood sample was requested
from all active participants in NHS and
collected from 32 826 women. Similarly,
blood samples were requested between
1993 and 1995 and obtained from 18
225 HPFS participants. As described ear-
lier, nested case-control studies of CHD
weredesignedwithinbothcohorts,allow-
ing the study to maintain a prospective design.32 Because
the laboratory measurements for the present study required a
large volume (0.600 mL), we restricted our study to those with
more than 2 mL plasma (Figure 1). Among participants who
were free of diagnosed cardiovascular disease or cancer at
blood draw, we identiﬁed 351 women in NHS and 437 men in
HPFS with incident CHD between blood draw and June, 2004.
Using risk-set sampling,33 controls were selected randomly
and matched in a 1:1 ratio on age (1 year), smoking (never,
past, current), and month of blood return, among participants
who were free of cardiovascular disease at the time CHD was
diagnosed in the case. The diagnosis of CHD included nonfatal
myocardial infarction and fatal CHD. The diagnosis of myocar-
dial infarction was conﬁrmed on the basis of the criteria of
the World Health Organization (symptoms plus either diagnos-
tic electrocardiographic changes or elevated levels of cardiac
enzymes). Deaths were identiﬁed from state vital records and
the National Death Index or reported by the participant’s next
of kin or the postal system. Fatal CHD was conﬁrmed by an
examination of hospital or autopsy records, by the listing of
CHD as the cause of death on the death certiﬁcate, if CHD
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was the underlying and most plausible cause, and if evidence
of previous CHD was available.
The study protocol was approved by the institutional review
board of the Brigham and Women’s Hospital and the Human
Subjects Committee Review Board of Harvard School of Public
Health.
Measurements
Demographic, anthropometric, and lifestyle data were derived
from questionnaires administered at blood draw (1990 in the
NHS and 1994 in the HPFS), with missing information substi-
tutedfrompreviousquestionnaires.Bodymassindex(BMI)was
calculated as the weight in kilograms divided by the square of
the height in meters. Physical activity was expressed in terms
ofmetabolicequivalenthours.Participantsreportedwhethera
physician had ever diagnosed them with diabetes or hyperten-
sion. The questionnaires and the validity and reproducibility of
measurements have been described previously.31 Blood sam-
ples were collectedin tubes treatedwithliquid sodium heparin
(in NHS) or EDTA (in HPFS). The tubes were then placed on ice
packs, stored in styrofoam containers, returned to our labora-
torybyovernightcourier,centrifuged,anddividedintoaliquots
for storage in liquid-nitrogen freezers (−130◦C or colder).
Immuno-afﬁnity chromatography was conducted with afﬁnity-
puriﬁed anti-human apoC-III (Academy Biomedical Company,
Inc., Houston, TX) to separate the plasma into fractions
with and without apoC-III. Detailed methods have been pub-
lished previously.34 Subsequently, apoC-III-bound and apoC-
III-unbound fractions were ultracentrifuged to isolate the very
low-density (d<1.006 g/mL), low-density (1.006<d<1.063
g/mL),andhigh-density(d>1.063g/mL)lipoproteinparticles.
The concentration of apoC-III in the bound fraction of HDL was
determined by ELISA, and cholesterol was measured in both
HDLfractionsenzymatically(ThermoScientiﬁc,Waltham,MA).
Liquid transfer for 96-well plate loading and ELISA dilutions
were handled robotically with a Multiprobe II (Perkin Elmer,
Waltham, MA) to minimize pipetting error. Both ELISA and
lipids plates were read with a BioTek ELx808iu 96-well plate
reader controlled by KCJunior software (BioTek, Winooski, VT).
All assays were completed in triplicate and any sample with an
intraassaycoefﬁcientofvariationmorethan15%wasrepeated.
One sample had to be reassessed for HDL-C with apoC-III and
30samplesfortheconcentrationofapoC-IIIinHDL.Eachbatch
in a laboratory analysis included the matched case-control
sets so that run-to-run variation in the analysis would not add
imprecision to the differences between cases and controls.
All laboratory personnel were blinded to the case-control sta-
tus. The within-run average CVs were 8% for HDL-C without
apoC-III, 13% for HDL-C with apoC-III, and 17% for apoC-III in
HDL.
A small fraction of the cholesterol in the standard HDL
d>1.063 fraction prepared by ultracentrifugation could be
transported in very dense LDL particles coisolated with HDL.
Sufﬁcient plasma volumes were available in the HPFS to re-
peat the measurement of cholesterol in HDL after precipita-
tion of any contaminating apoB lipoproteins by dextran sulfate
and magnesium chloride. These measurements were used in
the analyses presented in this report. In the NHS this di-
rect measurement was only possible in a subsample of 24
women with sufﬁcient plasma left. We used this subset with
both cholesterol measures in addition to measurements of
the apoB concentration to estimate the average cholesterol
per apoB particle in the d>1.063 fraction. The amount of
cholesterol that was estimated to be associated with apoB
particles in the d>1.063 fraction was 0.010 mmol/L in the
fraction with apoC-III and 0.007 mmol/L in the fraction with-
out apoC-III, comprising 4% and 0.5% of the fractions, respec-
tively. Subsequently we computed corrected HDL-C measures
for the NHS cohort by subtracting the cholesterol that was
associated with very dense LDL in each of the apoC-III com-
partments. These values were used in the analyses presented
in this report. Sensitivity analyses showed that the associa-
tions for total HDL-C and HDL-C without apoC-III were similar
before and after applying the correction, whereas the asso-
ciation for HDL-C with apoC-III was slightly weaker after the
correction.
We performed additional testing of our measurements on
a set of newly collected samples that were analyzed with the
above described methods in fresh state and after 6 days of
freezer storage. We did not see any difference in the obtained
valuesfortheconcentrationofHDL-CwithandwithoutapoC-III
from samples before and after storage.
Statistical Analysis
We performed the current analysis in all participants with
complete information on the HDL-C measures. After exclud-
ing participants with at least one value missing, we also ex-
cluded cases and controls that had no matching control or
case (Figure 1). Our ﬁnal data sets consisted of 572 in NHS
(286 case-control sets) and 699 in HPFS (348 case-control
sets; three cases had two matched controls). We compared
baseline characteristics of the cases and controls who were
part of versus those who were excluded from the analysis and
found no statistically signiﬁcant differences (Table, Appendix).
BaselinecharacteristicsofparticipantswhodevelopedCHD
during follow-up and controls were assessed in each cohort.
Multivariable-adjusted relationships between cardiovascular
risk factors and HDL-C with and without apoC-III were eval-
uated using mixed linear regression with a random effect for
each matched pair (PROC mixed). Cohort-speciﬁc quintiles of
lipid parameters were calculated using the distributions in the
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controls. Relative risks (RR) and 95% conﬁdence intervals (CIs)
for CHD risk were estimated by the incidence rate ratios from
conditionallogisticregressionanalysestakingintoaccountthe
matchingfactors(age,smoking,andtimeofblooddraw).33 Po-
tential confounders were selected on the basis of prior knowl-
edge of their role as cardiovascular risk factors or on the basis
of their association with our HDL-C exposures of interest. Be-
causeHDL-CwithandwithoutapoC-IIIsumstototalHDL-C,all
modelssimultaneouslyincludedthetwofractions.Pvaluesrep-
resent test of linear trend across quintiles. When no violations
of the linear assumptions were identiﬁed we also analyzed the
RR according to one standard deviation (SD) difference in total
HDL-C (0.6 mmol/L. For HDL-C without apoC-III we used 0.53
mmol/LandforHDL-CwithapoC-III0.07mmol/Ltorepresent
their relative proportions.). We tested for slope heterogeneity
of the two HDL subtypes with the null hypothesis of them
being equal. In the absence of between study heterogeneity,
estimatesfromthetwocohortswerepooledbyrandomeffects
meta-analysis.Insensitivityanalyses,wecomparedtheassoci-
ations from analyses in strata of 5 years of follow-up. Analyses
were performed using SAS 9 (SAS Institute Inc., Cary, NC).
Results
The NHS women were slightly younger, more likely to smoke,
more likely to self-report a history of diabetes and hyper-
cholesterolemia, and consumed less alcohol, compared with
theHPFSmen(Table1).BesidesexpecteddifferencesinLDL-C
and triglycerides levels, cases also had lower levels of HDL-C
withoutapoC-III.TheproportionofHDL-CthathadapoC-IIIwas
14% in the NHS and 11% in the men. It was slightly higher in
cases compared with controls in both sexes (P=0.07 in NHS
and P=0.01 in HPFS). The mean apoC-III concentration in HDL
did not differ according to case status.
Table 1. Baseline Characteristics of Women and Men in Whom Coronary Heart Disease Developed During Follow-Up and
Matched Controls in the Nurses’ Health Study (NHS) and the Health Professionals Follow-Up Study (HPFS)∗
NHS—Women HPFS—Men
Variable Cases (n=286) Controls (n=286) Cases (n=348) Controls (n=351)
Mean age (SD), y 60.2 (6.5) 60.1 (6.5) 64.3 (8.5) 64.2 (8.5)
Mean BMI (SD), kg/m2 26.8 (5.7) 25.3 (4.1) 26.1 (3.3) 25.5 (3.5)
Current smoker, % 26.6 25.9 8.1 7.7
Mean alcohol intake (SD), g/d 4.2 (8.0) 5.4 (9.4) 10.6 (15.5) 12.5 (15.0)
Physical activity (MET h/wk) 17.4 (20.7) 20.1 (21.4) 35.0 (36.5) 37.0 (38.1)
Caucasian ethnicity, % 98.6 99.7 98.0 98.3
Postmenopausal, % 86.7 84.6 N/A N/A
Estrogen replacement therapy, % 31.0 32.6 N/A N/A
Family history of MI, % 20.3 14.3 44.3 33.9
Diabetes, % 15.4 5.9 8.1 3.7
Hypercholesterolemia, % 54.2 41.6 47.7 39.3
Hypertension, % 53.9 31.8 36.8 29.1
Lipid/apoliprotein concentrations
Mean total cholesterol (SD), mmol/L 6.07 (1.20) 5.97 (1.22) 5.65 (0.77) 5.42 (0.96)
Median triglyceride level (IQR), mmol/L 1.2 (0.8–1.9) 1.0 (0.8–1.5) 1.3 (0.9–1.9) 1.1 (0.7–1.5)
Mean LDL-C (SD), mmol/L 3.84 (1.06) 3.69 (1.05) 3.50 (0.88) 3.26 (0.85)
Mean HDL-C (SD), mmol/L 1.76 (0.56) 1.88 (0.65) 1.21 (0.43) 1.26 (0.41)
Mean HDL-C without apoC-III (SD), mmol/L 1.52 (0.52) 1.64 (0.61) 1.07 (0.39) 1.12 (0.37)
Mean HDL-C with apoC-III (SD), mmol/L 0.25 (0.11) 0.24 (0.10) 0.14 (0.07) 0.14 (0.07)
Mean apoC-III in HDL (SD), g/L 0.12 (0.10) 0.12 (0.07) 0.12 (0.10) 0.11 (0.08)
∗ Matching criteria were: age, smoking, and date of blood sampling. Values are means ± SD of continuous covariates or percentages. Lipid and apolipoprotein measures are in SI units.
To convert cholesterol concentrations from mmol/L to mg/dL, divide by 0.0259. To convert ApoC-III from g/L to mg/dL, divide by 0.01. To convert triglycerides from mmol/L to mg/dL,
divide by 0.0113. Triglyceride levels were log-transformed before analysis and only reported in fasting participants (HPFS=65%, NHS=79%).
Diabetes, hypertension, and hypercholesterolemia were self-reported diagnosis before blood draw.
BMI indicates body mass index; MET, metabolic equivalent; MI, myocardial infarction;IQR, interquartile range
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Figure 2. Multivariate-adjusted percent differences in levels of HDL-C with and without apoC-III according to demographic, lifestyle, and clinical
factors in the NHS and the HPFS. Multivariate-adjusted regression analyses for the association of each factor with the log-transformed HDL levels,
adjusted for each variable simultaneously. Biomarkers were evaluated one at a time in multivariable-adjusted models. Mixed-effect models to
take matching into account. Estimates from the two cohorts were pooled using random-effects meta-analysis. No P values for test of between
study heterogeneity were lower than 0.5. All variables assessed at baseline (time of blood draw).
We analyzed whether lifestyle factors and biomarkers
known to be associated with cardiovascular risk were differen-
tiallyassociatedwithlevelsofHDL-CwithandwithoutapoC-III.
Compared with normal weight, overweight and obesity was as-
sociatedwith7%(P=0.0002)and12%(P=0.01)lowerlevelsof
HDL-CwithoutapoC-III,whereaselevatedbodymassindexwas
statisticallyinsigniﬁcantlyassociatedwithhigherlevelsofHDL-
CwithapoC-III(Figure2).Alcoholwasassociatedwithapproxi-
mately3%(P=0.04and0.01,respectively)higherlevelsofboth
HDL-C types per each 15 g/day. Smokers had 1% (P=0.04)
higher levels of HDL-C with apoC-III compared with nonsmo-
kers.LevelsofHDL-CwithoutapoC-IIIwere9%(P=0.02)higher
in premenopausal women and postmenopausal women who
received hormone replacement than postmenopausal women
who did not take hormones. We evaluated cardiovascular
biomarkers in separate models and found that higher triglyc-
eride levels were associated wit h higher levels of HDL-C with
apoC-III, and lower levels of HDL-C without apoC-III (both P =
0.001).
HDL-C With and Without ApoC-III and Risk for
Future CHD
Total HDL-C was inversely associated with risk of CHD in both
NHS and HPFS (Table 2). An even stronger inverse associa-
tion was observed across quintiles of HDL-C without apoC-III
in both cohorts. The associations appeared slightly stronger
in the NHS women than the HPFS men, but the tests of be-
tween study heterogeneity for the associations were not sig-
niﬁcant (P>0.5). When the cohort-speciﬁc results from mul-
tivariable analyses that adjusted for important demographics
and lifestyle factors were combined, the RR across extreme
quintiles of HDL-C without apoC-III was 0.31 (95% CI, 0.18–
0.55) in the combined cohort (Figure 3). Each SD increase
(0.53 mmol/L) predicted a RR of 0.66 (95% CI, 0.53–0.83;
Table 3). In contrast, higher levels of HDL-C with apoC-III were
not inversely associated with the risk of CHD. In the combined
cohorts, the RR for quintile 5 versus 1 was 1.62 (CI, 1.00–
2.61). Each SD increase in HDL-C with apoC-III (0.07 mmol/L)
was associated with an 18% (95% CI, 3–34%) higher risk of
future CHD. The slopes of the regression coefﬁcients for the
two HDL-C subtypes were statistically signiﬁcantly different
(P=0.02). Additional adjustment for triglycerides and apoB at-
tenuated the risk estimates for HDL-C with apoC-III but the
test of heterogeneity for slopes remained statistically signif-
icant (P=0.05). After additional adjustment for the potential
intermediate exposure, diabetes, the HDL-C with apoC-III was
no longer associated with the risk of CHD (RR per SD=1.02
[95% CI, 0.88–1.18]), whereas an inverse trend remained for
HDL-C without apoC-III (RR per SD=0.79 [95% CI, 0.62–1.01];
Table 3).
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Table 2. Incidence Rate Ratios (IRR) and 95% conﬁdence intervals of CHD According to Quintiles of Total HDL-C, HDL-C Without
ApoC-III and HDL-C With ApoC-III in the Nurses’ Health Study (NHS) and the Health Professionals Follow-Up Study (HPFS)
Q1 Q2 Q3 Q4 Q5 P trend
Total HDL-C
NHS (median, range) 1.17 (0.32–1.37) 1.53 (1.38–1.67) 1.81 (1.68–1.97) 2.12 (1.98–2.36) 2.68 (2.37–4.20)
Unadjusted 1.0 (ref) 0.86 (0.51–1.45) 0.67 (0.37–1.21) 0.70 (0.39–1.26) 0.32 (0.15–0.65) 0.003
Multivariate 1.0 (ref) 0.88 (0.50–1.54) 0.68 (0.36–1.30) 0.79 (0.41–1.51) 0.41 (0.18–0.92) 0.05
HPFS (median, range) 0.81 (0.22–0.93) 1.04 (0.93–1.14) 1.23 (1.14–1.33) 1.42 (1.33–1.58) 1.79 (1.58–3.59)
Unadjusted 1.0 (ref) 0.58 (0.36–0.94) 0.64 (0.38–1.07) 0.48 (0.27–0.84) 0.46 (0.25–0.85) 0.02
Multivariate 1.0 (ref) 0.59 (0.36–0.97) 0.68 (0.40–1.16) 0.54 (0.30–0.96) 0.53 (0.28–1.01) 0.07
HDL-C without ApoC-III
NHS (median, range) 0.95 (0.03–1.14) 1.32 (1.14–1.46) 1.59 (1.46–1.75) 1.88 (1.75–2.11) 2.39 (2.12–3.70)
Unadjusted 1.0 (ref) 0.90 (0.49–1.65) 0.57 (0.29–1.11) 0.58 (0.28–1.22) 0.20 (0.09–0.49) 0.0001
Multivariate 1.0 (ref) 1.03 (0.54–1.95) 0.68 (0.33–1.42) 0.74 (0.33–1.65) 0.30 (0.12–0.77) 0.006
HPFS (median, range) 0.71 (0.19–0.83) 0.90 (0.83–1.00) 1.09 (1.00–1.18) 1.27 (1.18–1.42) 1.61 (1.42–3.34)
Unadjusted 1.0 (ref) 0.39 (0.23–0.68) 0.52 (0.30–0.93) 0.32 (0.17–0.59) 0.26 (0.13–0.53) 0.006
Multivariate 1.0 (ref) 0.38 (0.21–0.67) 0.61 (0.34–1.09) 0.35 (0.19–0.66) 0.32 (0.16–0.66) 0.03
HDL-C with apoC-III
NHS (median, range) 0.12 (0.01–0.16) 0.16 (0.15–0.20) 0.23 (0.20–0.26) 0.28 (0.26–0.32) 0.39 (0.33–0.59)
Unadjusted 1.0 (ref) 0.86 (0.47–1.56) 1.12 (0.62–2.04) 1.09 (0.57–2.09) 1.58 (0.79–3.16) 0.08
Multivariate 1.0 (ref) 0.78 (0.41–1.46) 1.12 (0.60–2.11) 1.00 (0.51–1.99) 1.44 (0.69–3.01) 0.14
HPFS (median, range) 0.07 (0.01–0.08) 0.10 (0.09–0.11) 0.13 (0.12–0.14) 0.16 (0.14–0.18) 0.22 (0.18–0.51)
Unadjusted 1.0 (ref) 1.15 (0.69–1.93) 1.34 (0.80–2.32) 1.19 (0.66–2.15) 1.77 (0.96–3.24) 0.07
Multivariate 1.0 (ref) 1.10 (0.64–1.89) 1.32 (0.74–2.33) 1.19 (0.65–2.19) 1.76 (0.94–3.31) 0.08
Incidence rate ratios (IRR) obtained from conditional logistic regression models. Unadjusted model takes into account age and smoking (due to matching). Multivariate model includes:
alcohol, body mass index, self-reported diagnosis of hypertension before blood draw, and postmenopausal status and hormones in NHS only. HDL with and without apoC-III are
simultaneously included in all models. P trend is the test for linear trend across quintiles.
Investigation of Potential Effect-Modiﬁers
We addressed whether the observed associations for HDL-C
with and without apoC-III would be modiﬁed by important CVD
risk factors. We tested for the potential effect-modiﬁcation by
median triglycerides and did not observe any (P for interaction
HDL-C with and without apoC-III both >0.1). There was no
evidence of effect-modiﬁcation by hypercholesterolemia (both
P for interaction >0.1). We had few participants who reported
useofcholesterol-loweringdrugsatblooddrawin1990/1994,
but our results were not appreciably different when restricted
to participants who did not take cholesterol-lowering drugs.
Finally, the majority of the women were postmenopausal, and
33% of them reported use of estrogen replacement therapy
at baseline. In analyses among postmenopausal women alone
we observed very similar trends for HDL-C with and without
apoC-III in strata according to use of estrogen replacement
therapy (both P for interaction>0.1).
Concentration of apoC-III in HDL and Risk for
Future CHD
The concentration of apoC-III in HDL tended toward a direct
associationwithriskofCHDinbothcohorts.TheRRforhighest
versus lowest quintile in a multivariable-adjusted model with
additional adjustment for HDL-C was 1.42 (0.79 to 2.57), but
the trend across quintiles was also insigniﬁcant (P trend=0.2;
Table 4).
Discussion
ThecontroversiesinestablishingtheroleofHDLinatheroscle-
rosis may be due in part to the lack of speciﬁcity in the mea-
surements of HDL-C. In two independent prospective studies
of generally healthy middle-aged men and women, we found
that HDL is composed of two populations having opposite as-
sociations with CHD. The major HDL-C type lacking apoC-III
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Table 3. Incidence Rate Ratios (IRR) and 95% conﬁdence intervals of CHD According to Continuous Measures of Total HDL-C (per
0.60 mmol/L), HDL-C Without ApoC-III (per 0.53 mmol/L), and HDL-C with ApoC-III (per 0.07 mmol/L) in the Nurses’ Health
Study (NHS) and the Health Professionals Follow-Up Study (HPFS)
NHS HPFS Together
Per SD P Per SD P P het Per SD P
Total HDL-C
Unadjusted 0.69 (0.54–0.87) 0.002 0.70 (0.52–0.95) 0.02 0.9 0.69 (0.58–0.83) 0.0001
Adjusted 0.77 (0.59–1.01) 0.06 0.79 (0.57–1.10) 0.2 0.9 0.78 (0.63–0.96) 0.02
+ triglycerides and apoB 0.81 (0.61–1.07) 0.14 0.85 (0.61–1.18) 0.3 0.8 0.83 (0.68–1.01) 0.06
+d i a b e t e s 0.80 (0.60–1.05) 0.11 0.86 (0.61–1.20) 0.4 0.7 0.82 (0.66–1.02) 0.07
HDL without ApoC-III
Unadjusted 0.55 (0.42–0.73) 0.0001 0.61 (0.44–0.85) 0.003 0.6 0.58 (0.47–0.71) <0.0001
Adjusted 0.64 (0.47–0.87) 0.004 0.70 (0.50–0.97) 0.03 0.7 0.66 (0.53–0.83) 0.0001
+ triglycerides and apoB 0.70 (0.50–0.98) 0.04 0.85 (0.60–1.21) 0.4 0.4 0.77 (0.60–0.98) 0.03
+d i a b e t e s 0.73 (0.82–1.02) 0.07 0.87 (0.61–1.25) 0.4 0.5 0.79 (0.62–1.01) 0.06
HDL with ApoC-III
Unadjusted 1.16 (1.00–1.35) 0.05 1.20 (0.97–1.47) 0.09 0.8 1.17 (1.04–1.32) 0.01
Adjusted 1.16 (0.99–1.35) 0.07 1.21 (0.98–1.51) 0.08 0.7 1.18 (1.03–1.34) 0.01
+ triglycerides and apoB 1.10 (0.93–1.30) 0.3 1.00 (0.78–1.29) 0.9 0.6 1.07 (0.93–1.23) 0.4
+d i a b e t e s 1.04 (0.87–1.24) 0.6 0.97 (0.76–1.25) 0.8 0.7 1.02 (0.88–1.18) 0.8
Incidence rate ratios (IRR) obtained from conditional logistic regression models.Unadjusted model takes into account age and smoking (due to matching). Multivariate model includes:
alcohol, body mass index, self-reported diagnosis of hypertension before blood draw, and postmenopausal status and hormones in NHS only. HDL with and without apoC-III are
simultaneously included in all models. The NHS and HPFS data were combined using random effects meta-analyses. P het=P for test of between study heterogeneity
has the expected protective association with CHD, whereas
the small subfraction of HDL-C that has apoC-III present on its
surface (≈13%) tended to be associated with a higher risk of
future CHD.
Investigations of the metabolic heterogeneity of lipid par-
ticles are potentially valuable to improve understanding of
the atheroprotective or nonprotective effects of HDL. Al-
though previous large-scale studies have evaluated HDL
Table 4. Incidence Rate Ratios (IRR) and 95% conﬁdence intervals for CHD According Quintiles of ApoC-III in HDL in the Nurses’
Health Study (NHS) and the Health Professionals Follow-Up Study (HPFS)
Q1 Q2 Q3 Q4 Q5 P trend
NHS
Median (range) 0.03 (0.003–0.05) 0.07 (0.05–0.09) 0.10 (0.09–0.12) 0.15 (0.12–0.17) 0.22 (0.17–1.25)
Unadjusted 1.0 (ref) 1.55 (0.81–2.94) 1.19 (0.57–2.46) 1.20 (0.55–2.69) 1.51 (0.62–3.69) 0.6
Multivariate 1.0 (ref) 1.52 (0.76–3.04) 1.11 (0.51–2.41) 1.06 (0.46–2.43) 1.14 (0.44–2.97) 0.8
HPFS
Median (range) 0.04 (0.0004–0.06) 0.07 (0.05–0.08) 0.09 (0.08–0.11) 0.13 (0.11–0.16) 0.21 (0.16–0.72)
Unadjusted 1.0 (ref) 0.95 (0.57–1.59) 0.76 (0.43–1.36) 1.58 (0.89–2.80) 1.67 (0.82–3.41) 0.04
Multivariate 1.0 (ref) 1.03 (0.60–1.76) 0.77 (0.42–1.40) 1.60 (0.88–2.92) 1.63 (0.77–3.46) 0.07
Together
Unadjusted 1.0 (ref) 1.17 (0.73–1.86) 0.91 (0.58–1.42) 1.44 (0.91–2.28) 1.60 (0.92–2.80) 0.07
Multivariate 1.0 (ref) 1.29 (0.78–1.82) 0.88 (0.55–1.42) 1.39 (0.85–2.26) 1.42 (0.79–2.57) 0.2
Incidence rate ratios (IRR) obtained from conditional regression models. Unadjusted model takes into account age and smoking (due to matching). Multivariate model includes: alcohol,
body mass index, total HDL-C, self-reported diagnosis of hypertension before blood draw, and postmenopausal status and hormones in NHS only. The NHS and HPFS data were
combined using random effects meta-analyses. No P values for test of between study heterogeneity were lower than 0.5. P trend is the test for linear trend across quintiles.
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Figure 3. Multivariate-adjusted RRs for CHD according to quin-
tiles of total HDL-C, HDL-C with and without apoC-III in the com-
bined NHS and HPFS. RRs are incidence rate ratios (IRR) obtained
from conditional logistic regression models. Multivariate model takes
into account age and smoking due to matching. HDL-C with and
without apoC-III are simultaneously included. NHS and HPFS data
were combined using random effects meta-analyses. No P values
for test of between study heterogeneity were lower than 0.5. Error
bars indicate 95% conﬁdence interval. Adjusted for alcohol, body
mass index, self-reported diagnosis of hypertension before blood
draw, postmenopausal status, and hormones in NHS. The P for linear
trend across quintiles: total HDL-C=0.005; for HDL-C without apoC-
III=0.007; HDL-C with apoC-III=0.02. P for test of difference in slope
between HDL-C with and without apoC-III=0.02.
subpopulations separated by size,21 whether such measure-
ments improve cardiovascular risk prediction remains uncer-
tain as the ﬁndings have been inconsistent.15,35 Other more
experimental subclassiﬁcations include the effect of HDL on
cholesterol efﬂux or anti-inﬂammatory activities of HDL.36
These new experimental assays are of scientiﬁc interest and
suggest that the measure of total HDL-C may be diluted due to
a mixing of cholesterol distributed in both anti- and proathero-
genic HDL particles. However, so far, the concept and under-
standing of what makes a dysfunctional or even proinﬂam-
matory HDL subtype remains elusive.14,37 Our data suggest
that apoC-III may confer atherogenic properties to HDL that
potentially could overcome other beneﬁcial components. We
observed that the apoC-III concentration in HDL was not sig-
niﬁcantly associated with CHD, indicating that the concentra-
tion of HDL-C with any apoC-III may be more relevant to the
risk of CHD than how much apoC-IIII is in the HDL. Previous
studies have only addressed the latter question. In the CLAS
trial, the concentration of apoC-III in HDL was inversely asso-
ciated with the progression of CAD in the drug-treated group
of CAD patients only,38 whereas a direct, but not statistically
signiﬁcant, association with CHD and re-current events was
reported in two larger studies.26,39 These studies were either
cross sectional39 or conducted in a patient population with
existing CVD.26 Because the concentration of apoC-III may be
affected by disease status, it may be particularly important
to study this in a prospective setting in populations that did
not have clinical CVD at baseline. For the metabolism of en-
tire lipoprotein particles, it is likely that the presence (if any)
versus absence of apoC-III may determine the downstream in-
teractions with receptors and enzymes.22,40. Kawakami et al25
reported that HDL without apoC-III, but not HDL with apoC-III,
limits the proinﬂammatory adhesion of human monocytes to
endothelial cells. ApoC-III also plays an important role in the
catabolism of triglyceride-rich lipoproteins through the inhibi-
tionofclearanceofplasmaVLDLandLDLbytheliver.41–43 Itis
possible that apoC-III functions similarly in HDL circulating in
blood, impairing delivery of HDL-C to the liver. However, it re-
mains a possibility that apoC-III is a marker for other attributes
of HDL that are related to atherosclerosis.
Lifestyle factors may modulate the distribution of choles-
terol within the two HDL fractions. We found that alcohol in-
take was similarly associated with both HDL-C subfractions,
whereas body weight and estrogens were only associated with
HDL-C without apoC-III. Other unmeasured confounders can-
not be excluded.
We used the concentration of cholesterol in HDL as our
measure of HDL. It is possible that our results could be reﬁned
by assessing alternative measures, such as the concentration
of apoA-I, the major apolipoprotein component of HDL, in-
stead. It is among our study limitations that we only had one
assessment of the lipid subfractions. Thus, our ﬁndings cannot
determine whether changes in the proportions of cholesterol
transported in HDL particles with and without apoC-III are
causally related to risk of CHD. Furthermore, the immunoafﬁn-
ity chromatography approach is a lengthy procedure and non-
differential measurement error might have diluted our relative
risk estimates. Earlier studies of apoC-III in lipoprotein frac-
tions have reported concern about redistribution of apoC-III
fromapoB-containinglipoproteinstoHDLduringstorage.44 We
did not detect instability in our measures of HDL-C with (any)
apoC-III and HDL-C without apoC-III in our own assessment
of samples that were analyzed both fresh and after freezer
storage. Use of different methodologies for the separation
of the apoC-III—containing lipoprotein fractions may be one
explanation.
Although our nested case-control study was prospective in
nature,undiagnosedillnessatbaselinemightcreateaspurious
association. We compared the associations from analyses in
strata of 5 years of follow-up. The results were similar to those
presented here both when cases that occurred during the ﬁrst
ﬁve and subsequent years of follow-up were considered (data
not shown).
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In conclusion, we found that HDL-C with and without apoC-
III showed opposite associations with the risk of CHD in
prospective studies of apparently healthy men and women.
On adjustment for a proatherogenic lipid proﬁle and diabetes,
HDL-CwithapoC-IIIwasnolongerassociatedwithriskofCHD,
but there was no evidence for an inverse association. Our ﬁnd-
ings highlight that HDL comprises a group of particles that
may be more or less closely linked with atherosclerosis. HDL
that has apoC-III may represent a dysfunctional HDL lacking
its cardioprotective function. This may also have implications
for future development novel therapeutic interventions aimed
at HDL elevation, as the cardioprotective beneﬁts may differ
depending on the affected HDL subfraction.
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